Asia Pacific Liquid Biopsy Market Size & Outlook
Asia Pacific liquid biopsy market, 2018-2030 (US$M)
Related Markets
Asia Pacific liquid biopsy market highlights
- The Asia Pacific liquid biopsy market generated a revenue of USD 1,525.3 million in 2023.
- The market is expected to grow at a CAGR of 13.4% from 2024 to 2030.
- In terms of segment, blood sample was the largest revenue generating type in 2023.
- Blood Sample is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, South Korea is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 1,525.3 million |
| Market revenue in 2030 | USD 3,678.2 million |
| Growth rate | 13.4% (CAGR from 2023 to 2030) |
| Largest segment | Blood sample |
| Fastest growing segment | Blood Sample |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Sample |
| Key market players worldwide | ANGLE PLC, Guardant Health Inc, Myriad Genetics Inc, Biocept Inc, Lucence Health, Roche, Qiagen NV, Illumina Inc, Thermo Fisher Scientific Inc, Epigenomics AG, Oncimmune, Freenome |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 14.3% of the global liquid biopsy market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 3,678.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Liquid Biopsy Market Scope
Liquid Biopsy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific liquid biopsy market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to liquid biopsy market will help companies and investors design strategic landscapes.
Blood sample was the largest segment with a revenue share of 73.27% in 2023. Horizon Databook has segmented the Asia Pacific liquid biopsy market based on blood sample covering the revenue growth of each sub-segment from 2018 to 2030.
The liquid biopsy market in Asia Pacific is expected to grow at the fastest rate over the forecast period due to various factors, such as improving healthcare reforms. Some of the other factors contributing to market growth are increasing population, improving healthcare infrastructure, and entry of new players.
For instance, in February 2020, Chugai Pharmaceutical Co., Ltd. and Foundation Medicine, Inc. signed an agreement with the National Cancer Center Japan to use Foundation One Liquid, a liquid biopsy test developed by Foundation Medicine's laboratory.
Implementation of tests for melanoma diagnoses in more institutes, such as the Olivia Newton-John Cancer Research Institute (ONJCRI) in Melbourne, is anticipated to boost the market. However, low affordability, poor infrastructure, and a lack of trained professionals may restrain the growth of the liquid biopsy market.
Reasons to subscribe to Asia Pacific liquid biopsy market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific liquid biopsy market databook
-
Our clientele includes a mix of liquid biopsy market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific liquid biopsy market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific liquid biopsy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific liquid biopsy market size, by country, 2018-2030 (US$M)
Asia Pacific Liquid Biopsy Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
